The Role of Cytokine IL-2 In Cancer Immunotherapy
DOI:
https://doi.org/10.54097/swakp429Keywords:
IL-2; Cytokine; Immunotherapy; Cancer.Abstract
Cancer remains a leading global cause of mortality, distinguished by its propensity for rapid proliferation, metastatic potential, and the ability to affect various organs with ease. If left untreated, it may lead to nerve compression, rupture of blood vessels, multi-organ failure, and may ultimately lead to the patient's death. The ability of immunotherapy to block signaling pathways that inhibit immune cell activation, enhance and amplify anti-tumor responses, or increase the amount of anti-tumor response cells makes it an important weapon in the fight against cancer. Among the key domains of cancer immunotherapy research, harnessing cytokines to invigorate anti-tumor reactions in cancer patients ranks as one of the foremost areas, given cytokines' capacity to regulate the host's immune reaction against cancer cells. Interleukin-2 (IL-2) is a recognized T-cell growth factor that has been used to treat metastatic melanoma. While extensive research has substantiated IL-2's potential in cancer therapy by impacting the immune system, its practical utility has encountered several constraints. This review centers on the diverse applications of IL-2-based cancer therapy, their underlying mechanisms, the associated limitations, and prospects for the future of IL-2 in the realm of cancer immunotherapy.
Downloads
References
Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature. 1977 Jul 14;268(5616):154-6.
Taniguchi, T., Matsui, H., Fujita, T. et al. Structure and expression of a cloned cDNA for human interleukin 2. Nature 302, 305–310 (1983).
Dehghan R, Beig Parikhani A, Zeinali S, Shokrgozar M, Amanzadeh A, Ajdary S, Ahangari Cohan R, Talebkhan Y, Behdani M. Efficacy and antitumor activity of a mutant type of interleukin 2. Sci Rep. 2022 Mar 30;12(1):5376.
Hernandez R, Põder J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022 Oct;22(10):614-628.
Sun Z, Ren Z, Yang K, Liu Z, Cao S, Deng S, Xu L, Liang Y, Guo J, Bian Y, Xu H, Shi J, Wang F, Fu YX, Peng H. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat Commun. 2019 Aug 28;10(1):3874.
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485-92.
Lim SH, Newland AC, Kelsey S, Bell A, Offerman E, Rist C, Gozzard D, Bareford D, Smith MP, Goldstone AH. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study. Cancer Immunol Immunother. 1992;34(5):337-42.
Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016 Apr 25;5(6):e1163462.
Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997 Jul;15(7):2579-88.
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α-2b. J Clin Oncol 1999;17:968–75.
Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002 Oct;8(10):3075-81.
Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2353s-2358s. doi: 10.1158/1078-0432.CCR-05-2503. PMID: 16609058.
Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008 Sep 1;14(17):5610-8.
Liu C, Xie Y, Sun B, Geng F, Zhang F, Guo Q, Wu H, Yu B, Wu J, Yu X, Kong W, Zhang H. MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model. Scand J Immunol. 2018 Feb;87(2):63-72.
Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ, Chen RF. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Oncol Lett. 2017 Apr;13(4):2198-2206.
Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003 Aug;5(8):690-9.
Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011 Nov;12(12):1125-33.
Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec;12(12):1005-16.
West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013 Jun;123(6):2604-15.
Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 Feb 18;7(1):49.
Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012 Mar 25;484(7395):529-33.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
